Children with atopic dermatitis need safer and more effective treatments

2022-05-08 0 By

Atopic dermatitis is a common disease with high incidence in childhood.It is a systemic immune disease caused by a type 2 inflammatory response and has often been described simply as “eczema”.It was found that the patients with moderate and severe atopic dermatitis in China suffered from atopic dermatitis for nearly 10 years on average and were often complicated with allergic rhinitis, asthma and other type 2 inflammatory diseases.Eighty-five to 90% of patients with atopic dermatitis are younger than five years of age at the time of symptom onset or onset and have not received effective treatment for many years by childhood.It is reported that children with episodes in atopic dermatitis, skin often appear the symptom of severe itching and skin lesions, cause skin cracking, erythema, papules, seepage, the serious influence children’s study life, physical and mental development and health growth, including psychological mood, sleep, concentration and quality of life, even may appear the psychological problems such as anxiety, depression,Most of the children’s parents will also lack of sleep, mental stress.However, children are at a critical stage of growth and development, and their healthy growth is related to the future of their families and countries. Therefore, safety is the most important consideration in terms of treatment for these patients.Dupriuzumab injection, a first-line innovative treatment for atopic dermatitis, has been approved by the State Medical Products Administration of China, expanding its use in the treatment of moderate and severe atopic dermatitis in children and adults aged 6 years and older who are poorly controlled or not recommended to use external drugs.The approval of this pediatric indication means that it is the only targeted biologic approved for the treatment of moderate to severe atopic dermatitis in children, adolescents and adults in China, and will bring a new safe and effective treatment option to a wider patient population.According to Yao Zhirong, director of the dermatology department at Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, atopic dermatitis is mostly mild and can be well controlled with conventional treatment, but there are still some cases that are resistant to existing treatment and have poor symptom control.Multiple clinical studies and real-world studies have confirmed that Dupriuzumab injection can be effective and safe, without inhibiting growth and development, which is of great significance for long-term disease control and improvement of life quality in children with atopic dermatitis.The drug has been approved in more than 60 countries and regions around the world. It is the first targeted biological agent for the treatment of moderate to severe atopic dermatitis, and more than 350,000 patients have received effective treatment.Statement: The copyright of this article belongs to the original author, if there is a source error or infringement of your legitimate rights and interests, you can contact us through the mailbox, we will deal with it in time.Email address: